Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

• Type of Material: Article
• Authors: Lisa Kobrynski, Emory University
• Language: English
• Date: 2012-08-24
• Publisher: Dove Medical Press
• Publication Version: Final Published Version
• Copyright Statement: © 2012 Kobrynski, publisher and licensee Dove Medical Press Ltd.
• License: Creative Commons Attribution 2.5 Generic
• Final Published Version (URL): http://www.dovepress.com/subcutaneous-immunoglobulin-therapy-a-new-option-for-patients-with-pri-peer-reviewed-article-BTT
• Title of Journal or Parent Work: Biologics: Targets and Therapy
• ISSN: 1177-5475
• Volume: 2012
• Issue: 6
• Start Page: 277
• End Page: 287
• Keywords: subcutaneous immunoglobulin; immunoglobulin G; primary immunodeficiency diseases
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Health Care Management

Abstract

Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3–4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.